- Supported exchanges /
- F /
- 9U90.F
UNITY BIOTECHN. DL-0001 (9U90 F) stock market data APIs
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
UNITY BIOTECHN. DL-0001 Financial Data Overview
| 1.254 | |
| 1.254 | |
| - | |
| 1.254 | |
| 1.254 | |
| 1.148-1.911 | |
| 17 580 K | |
| 0 | |
| 0 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
UNITY BIOTECHN. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get UNITY BIOTECHN. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get UNITY BIOTECHN. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
